How Does IDEXX Laboratories Make its Money?
IDEXX Laboratories is the global leader in veterinary diagnostics, providing in-clinic analyzers, reference laboratory services, rapid assay test kits, and practice management software to veterinary practices worldwide. The company dominates the companion animal (pet) diagnostics market with an estimated 50%+ global share. IDEXX’s instruments are placed in veterinary clinics under a razor-and-blade model — the company sells or leases analyzers and then generates recurring revenue from consumables, tests, and reference lab services. With pet ownership growing, vet visits increasing, and the humanization of pets driving demand for advanced diagnostics, IDEXX benefits from powerful secular tailwinds.
IDEXX Laboratories (IDXX) Business Model
IDEXX Laboratories operates in the healthcare sector. Below is a summary of IDEXX Laboratories’ revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from IDEXX Laboratories’ 2024 fiscal year filings with the SEC.
IDEXX Laboratories Competitors
IDEXX Laboratories’s key competitors and comparable public companies in the healthcare sector include Zoetis, Danaher, Thermo Fisher Scientific, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IDEXX Laboratories stacks up by comparing their revenue breakdown, margins, and growth metrics.
IDEXX Laboratories Competitors
IDEXX Laboratories’s key competitors and comparable public companies in the healthcare sector include Zoetis, Danaher, Thermo Fisher Scientific, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IDEXX Laboratories stacks up by comparing their revenue breakdown, margins, and growth metrics.
IDEXX Laboratories Competitors
IDEXX Laboratories’s key competitors and comparable public companies in the healthcare sector include Zoetis, Danaher, Thermo Fisher Scientific, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IDEXX Laboratories stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Companion Animal Group (CAG) Diagnostics | $3,200 | $2,900 | +10.3% |
| CAG Reference Laboratory Services | $1,100 | $1,000 | +10.0% |
| Water (Microbiology Testing) | $200 | $180 | +11.1% |
| Livestock, Poultry & Dairy (LPD) | $200 | $190 | +5.3% |
| Total Revenue | $3,900 | $3,700 | +5.4% |
Companion Animal Group (CAG) Diagnostics — 82% of Revenue
CAG Reference Laboratory Services — 28% of Revenue
Water (Microbiology Testing) — 5% of Revenue
Livestock, Poultry & Dairy (LPD) — 5% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3,900 | $3,700 |
| Cost of Revenue | $1,600 | $1,500 |
| Gross Profit | $2,300 | $2,200 |
| Operating Expenses | $1,000 | $950 |
| Operating Income | $1,300 | $1,250 |
| Net Income | $1,000 | $950 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 59.0%
- Operating Margin: 33.3%
- Revenue Growth: 5.4%
Is IDEXX Laboratories Profitable?
Yes, IDEXX Laboratories is profitable. The company reported net income of $1,000 on total revenue of $3,900. With an operating margin of 33.3%, IDEXX Laboratories demonstrates solid profitability for the healthcare sector. The gross margin of 59.0% reflects IDEXX Laboratories’ pricing power and cost structure.
What to Watch
- Companion animal clinical visit trends and same-store diagnostic revenue per visit
- Premium instrument placement growth (ProCyte One, Catalyst One, SediVue) in clinics
- International market penetration, particularly in Europe and Asia-Pacific
- Software and data analytics ecosystem expansion to drive recurring revenue
IDEXX Laboratories (IDXX) Financial Summary
IDEXX Laboratories (IDXX) is a healthcare company that generated $3,900 in total revenue in fiscal year 2024. Revenue grew 5.4% year-over-year. The company earned $1,000 in net income, making it profitable. For a deeper look at IDEXX Laboratories’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.